Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

About this update from Sunshine Biopharma Inc.

[{"type":"text","content":"FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication.","length":544,"tagName":"p"},{"type":"text","content":"The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a critical viral enzyme (PLpro) responsible for suppression of the human immune system, making Coronavirus infections life-threatening.","length":302,"tagName":"p"},{"type":"text","content":"Coronaviruses are known for their high mutation rate, a biological characteristic that has already produced multiple variants of concern since 2020. Each new mutation has the potential to alter transmissibility, disease severity, or resistance to existing treatments and vaccines. Scientific experts worldwide continue to warn that Coronavirus remains one mutation away from triggering another global health crisis.","length":415,"tagName":"p"},{"type":"text","content":"Sunshine Biopharma's patented technology is designed with this evolutionary reality in mind. By targeting a highly conserved viral function, the Company aims to develop antiviral candidates that remain effective even as the virus continues to mutate.","length":254,"tagName":"p"},{"type":"text","content":""The issuance of this patent is a major milestone for Sunshine Biopharma and a validation of our scientific strategy," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Coronaviruses mutate rapidly, and the world cannot assume the threat has passed. Our goal is to advance therapies that can help address not only today's variants but also those that may emerge in the future."","length":403,"tagName":"p"},{"type":"text","content":"The compounds covered under U.S. Patent 12,624,066 B2 are currently ready for GLP studies which is the step necessary to be completed before entering clinical trials. Sunsh...

More updates from Sunshine Biopharma Inc.